Հումալոգ

Հիմնական տեղեկություններ

  • Ֆիրմային անվանումը:
  • Հումալոգ
  • Դոզան:
  • 100ՄՄ/մլ (3,5մգ/մլ)
  • Դեղագործական ձեւ:
  • լուծույթ ներարկման
  • Միավորները փաթեթում:
  • (5) փամփուշտներ 3մլ
  • Ռեկվիզորի տեսակը:
  • Դեղատոմսով
  • Բժշկության տիրույթում:
  • Մարդիկ
  • Բժշկության տեսակ:
  • Ալլոպատիկ դեղամիջոց
  • Պատրաստված է:
  • Լիլի Ֆրանս Ս.Ա.Ս.

Փաստաթղթեր

  • Հանրության համար:
  • Այս ապրանքի տեղեկատվական թերթիկը ներկայումս մատչելի չէ, դուք կարող եք խնդրանքը ուղարկել մեր հաճախորդների սպասարկմանը եւ մենք կտեղեկացնենք այն ժամանակ, երբ մենք կարող ենք ձեռք բերել այն:


    Տեղեկատվության թերթիկից պահանջել հանրությանը:

Տեղայնացումը

  • Հասանելի է:
  • Հումալոգ
    አርሜኒያ
  • Լեզու:
  • አማርኛ

Այլ տեղեկություններ

Կարգավիճակը

  • Աղբյուրը:
  • Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում - Armenia
  • Վերջին թարմացումը:
  • 09-08-2016
  • Այս ապրանքի տեղեկատվական թերթիկը ներկայումս մատչելի չէ, դուք կարող եք խնդրանքը ուղարկել մեր հաճախորդների սպասարկմանը եւ մենք կտեղեկացնենք այն ժամանակ, երբ մենք կարող ենք ձեռք բերել այն:

    Տեղեկատվության թերթիկից պահանջել հանրությանը:



  • Այլ լեզուներով փաստաթղթերը հասանելի են Այստեղ
  • Այս փաստաթուղթը հասանելի է միայն գրանցված օգտագործողների համար:

    Register now for full access

7-2-2018

FDA Drug Safety Communication: Update to ongoing safety review of Lantus (insulin glargine) and possible risk of cancer

FDA Drug Safety Communication: Update to ongoing safety review of Lantus (insulin glargine) and possible risk of cancer

[1-12-2011] The U.S. Food and Drug Administration (FDA) is updating the public about its ongoing safety review of Lantus (insulin glargine) and a possible increased risk of cancer.

FDA - U.S. Food and Drug Administration

26-1-2018

Pending EC decision:  Semglee, insulin glargine, Opinion date: 25-Jan-2018

Pending EC decision: Semglee, insulin glargine, Opinion date: 25-Jan-2018

Europe - EMA - European Medicines Agency

11-12-2017

FDA approves Admelog, the first short-acting "follow-on" insulin product to treat diabetes

FDA approves Admelog, the first short-acting "follow-on" insulin product to treat diabetes

The FDA today approved Admelog (insulin lispro injection), a short-acting insulin indicated to improve control in blood sugar levels in adults and pediatric patients 3 years and older with type 1 diabetes mellitus and adults with type 2 diabetes mellitus. Admelog is the first short-acting insulin approved as a “follow-on” product.

FDA - U.S. Food and Drug Administration

23-4-2018

Suliqua (Sanofi-Aventis groupe)

Suliqua (Sanofi-Aventis groupe)

Suliqua (Active substance: insulin glargine / lixisenatide) - Centralised - Yearly update - Commission Decision (2018)2499 of Mon, 23 Apr 2018

Europe -DG Health and Food Safety

16-4-2018

Actrapid (Novo Nordisk A/S)

Actrapid (Novo Nordisk A/S)

Actrapid (Active substance: Insulin human (rDNA)) - Centralised - Yearly update - Commission Decision (2018)2301 of Mon, 16 Apr 2018

Europe -DG Health and Food Safety

16-4-2018

Actraphane (Novo Nordisk A/S)

Actraphane (Novo Nordisk A/S)

Actraphane (Active substance: Insulin human (rDNA)) - Centralised - Yearly update - Commission Decision (2018)2312 of Mon, 16 Apr 2018

Europe -DG Health and Food Safety

16-4-2018

Fiasp (Novo Nordisk A/S)

Fiasp (Novo Nordisk A/S)

Fiasp (Active substance: insulin aspart) - Centralised - 2-Monthly update - Commission Decision (2018)2309 of Mon, 16 Apr 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/4046/II/3/G

Europe -DG Health and Food Safety

28-3-2018

Courtney Lias and Stayce Beck paved the way for an automated insulin dosing system to receive FDA approval years earlier than expected, helping to make a groundbreaking new device for diabetes management available for Americans with Type 1 diabetes #Women

Courtney Lias and Stayce Beck paved the way for an automated insulin dosing system to receive FDA approval years earlier than expected, helping to make a groundbreaking new device for diabetes management available for Americans with Type 1 diabetes #Women

Courtney Lias and Stayce Beck paved the way for an automated insulin dosing system to receive FDA approval years earlier than expected, helping to make a groundbreaking new device for diabetes management available for Americans with Type 1 diabetes #WomensHistoryMonth pic.twitter.com/t1EyVQAh8t

FDA - U.S. Food and Drug Administration

28-3-2018

TRESIBA (Insulin Degludec Injection) Injection, Solution [Novo Nordisk]

TRESIBA (Insulin Degludec Injection) Injection, Solution [Novo Nordisk]

Updated Date: Mar 28, 2018 EST

US - DailyMed

27-3-2018

Semglee (Mylan S.A.S.)

Semglee (Mylan S.A.S.)

Semglee (Active substance: Insulin glargine) - Centralised - Authorisation - Commission Decision (2018)1952 of Tue, 27 Mar 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/4280

Europe -DG Health and Food Safety

23-3-2018

News and press releases:  Colour change for insulin injection Fiasp to avoid mix ups with Tresiba

News and press releases: Colour change for insulin injection Fiasp to avoid mix ups with Tresiba

Cartridges, pre-filled pens and vials changing from yellow to red and yellow

Europe - EMA - European Medicines Agency

5-3-2018

Insulatard (Novo Nordisk A/S)

Insulatard (Novo Nordisk A/S)

Insulatard (Active substance: Insulin human (rDNA)) - Centralised - Yearly update - Commission Decision (2018)1412 of Mon, 05 Mar 2018

Europe -DG Health and Food Safety

5-3-2018

Protaphane (Novo Nordisk A/S)

Protaphane (Novo Nordisk A/S)

Protaphane (Active substance: Insulin human (rDNA)) - Centralised - Yearly update - Commission Decision (2018)1413 of Mon, 05 Mar 2018

Europe -DG Health and Food Safety

5-3-2018

Mixtard (Novo Nordisk A/S)

Mixtard (Novo Nordisk A/S)

Mixtard (Active substance: Insulin human (rDNA)) - Centralised - Yearly update - Commission Decision (2018)1415 of Mon, 05 Mar 2018

Europe -DG Health and Food Safety

1-3-2018

Abasaglar (Eli Lilly Nederland B.V.)

Abasaglar (Eli Lilly Nederland B.V.)

Abasaglar (Active substance: Insulin glargine) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)1376 of Thu, 01 Mar 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/2835/T/18

Europe -DG Health and Food Safety

13-2-2018

Experts Questioning Study on Insulin Quality

Experts Questioning Study on Insulin Quality

Title: Experts Questioning Study on Insulin QualityCategory: Health NewsCreated: 2/9/2018 12:00:00 AMLast Editorial Review: 2/12/2018 12:00:00 AM

US - MedicineNet

7-2-2018

Scientific guideline:  Draft guideline on clinical investigation of medicinal products in the treatment or prevention of diabetes mellitus - Revision 2, draft: consultation open

Scientific guideline: Draft guideline on clinical investigation of medicinal products in the treatment or prevention of diabetes mellitus - Revision 2, draft: consultation open

Diabetes mellitus is a metabolic disorder characterised by the presence of hyperglycaemia due to defective insulin secretion, insulin action or both. The chronic hyperglycaemia of diabetes mellitus is associated with significant long term sequelae, particularly damage, dysfunction and failure of various organs – especially the kidneys, eyes, nerves, heart and blood vessels.

Europe - EMA - European Medicines Agency

7-2-2018

Insulin Resistance

Insulin Resistance

Title: Insulin ResistanceCategory: Diseases and ConditionsCreated: 2/10/2004 12:00:00 AMLast Editorial Review: 2/7/2018 12:00:00 AM

US - MedicineNet

1-2-2018

Cozaar vs. Avapro

Cozaar vs. Avapro

Cozaar (losartan) and Avapro (irbesartan) are angiotensin receptor blockers (ARBs) used to treat hypertension. Avapro is also sometimes given together with other blood pressure medications. Avapro is also used to treat kidney problems caused by type 2 (non-insulin-dependent) diabetes.

US - RxList

31-1-2018

NOVOLOG MIX 70/30 (Insulin Aspart) Injection, Suspension [A-S Medication Solutions]

NOVOLOG MIX 70/30 (Insulin Aspart) Injection, Suspension [A-S Medication Solutions]

Updated Date: Jan 31, 2018 EST

US - DailyMed

31-1-2018

TOUJEO (Insulin Glargine) Injection, Solution [A-S Medication Solutions]

TOUJEO (Insulin Glargine) Injection, Solution [A-S Medication Solutions]

Updated Date: Jan 31, 2018 EST

US - DailyMed

16-1-2018

Insulin Vials and Pens May Not Contain Sufficient Insulin

Insulin Vials and Pens May Not Contain Sufficient Insulin

Insulin vials and cartridges sold in pharmacies may not contain sufficient concentrations of insulin, new research finds.

US - RxList

16-1-2018

Insulin Vials and Pens May Not Be Accurate

Insulin Vials and Pens May Not Be Accurate

Insulin Vials and Pens May Not Contain Sufficient Insulin

US - eMedicineHealth

2-1-2018

Insulin Human Winthrop (Sanofi-Aventis Deutschland GmbH)

Insulin Human Winthrop (Sanofi-Aventis Deutschland GmbH)

Insulin Human Winthrop (Active substance: Insulin human) - Centralised - Yearly update - Commission Decision (2017)9099 of Tue, 02 Jan 2018

Europe -DG Health and Food Safety

20-12-2017

NovoMix (Novo Nordisk A/S)

NovoMix (Novo Nordisk A/S)

NovoMix (Active substance: Insulin aspart) - Centralised - Yearly update - Commission Decision (2017) 8993 of Wed, 20 Dec 2017

Europe -DG Health and Food Safety

12-12-2017

ADMELOG (Insulin Lispro) Injection, Solution [Sanofi-Aventis U.S. LLC]

ADMELOG (Insulin Lispro) Injection, Solution [Sanofi-Aventis U.S. LLC]

Updated Date: Dec 12, 2017 EST

US - DailyMed

7-12-2017

LEVEMIR (Insulin Detemir) Injection, Solution [A-S Medication Solutions]

LEVEMIR (Insulin Detemir) Injection, Solution [A-S Medication Solutions]

Updated Date: Dec 7, 2017 EST

US - DailyMed

22-11-2017

Insulin Pill May Delay Type 1 Diabetes in Some

Insulin Pill May Delay Type 1 Diabetes in Some

Title: Insulin Pill May Delay Type 1 Diabetes in SomeCategory: Health NewsCreated: 11/21/2017 12:00:00 AMLast Editorial Review: 11/22/2017 12:00:00 AM

US - MedicineNet

22-11-2017

HUMULIN R (Insulin Human) Injection, Solution [Eli Lilly And Company
]

HUMULIN R (Insulin Human) Injection, Solution [Eli Lilly And Company ]

Updated Date: Nov 22, 2017 EST

US - DailyMed

20-11-2017

Levemir (Novo Nordisk A/S)

Levemir (Novo Nordisk A/S)

Levemir (Active substance: insulin detemir) - Centralised - Yearly update - Commission Decision (2017)7796 of Mon, 20 Nov 2017

Europe -DG Health and Food Safety